Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.

Mol Psychiatry. 2004 Jul;9(7):705-10.

PMID:
14699432
3.

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.

Mitchell AJ.

J Neurol Neurosurg Psychiatry. 2009 Sep;80(9):966-75. doi: 10.1136/jnnp.2008.167791. Epub 2009 May 21. Review.

PMID:
19465413
4.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
5.

[Diagnosing the mild cognitive impairment stage of Alzheimer's disease].

Maruyama M, Matsui T, Tanji H, Ootsuki M, Nemoto M, Tomita N, Okamura N, Matsushita S, Higuchi S, Kodama M, Arai H, Sasaki H.

Seishin Shinkeigaku Zasshi. 2004;106(3):269-80. Review. Japanese.

PMID:
15164576
6.

Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.

Sjögren M, Andreasen N, Blennow K.

Clin Chim Acta. 2003 Jun;332(1-2):1-10. Review.

PMID:
12763273
7.

Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design.

van Rossum IA, Vos S, Handels R, Visser PJ.

J Alzheimers Dis. 2010;20(3):881-91. doi: 10.3233/JAD-2010-091606. Review.

PMID:
20413876
8.

CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.

Andreasen N, Sjögren M, Blennow K.

World J Biol Psychiatry. 2003 Oct;4(4):147-55. Review.

PMID:
14608585
9.

Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.

Marksteiner J, Hinterhuber H, Humpel C.

Drugs Today (Barc). 2007 Jun;43(6):423-31. Review.

PMID:
17612711
10.

CSF biomarkers for mild cognitive impairment.

Blennow K.

J Intern Med. 2004 Sep;256(3):224-34. Review.

11.
12.
13.

[Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].

Shoji M.

Rinsho Byori. 2006 May;54(5):503-8. Review. Japanese.

PMID:
16789421
14.

Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.

Galasko D.

J Neural Transm Suppl. 1998;53:209-21. Review.

PMID:
9700659
15.

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Blennow K, Vanmechelen E, Hampel H.

Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97. Review.

PMID:
11831556
16.

Cerebrospinal fluid biomarkers for Alzheimer's disease.

Blennow K, Zetterberg H.

J Alzheimers Dis. 2009;18(2):413-7. doi: 10.3233/JAD-2009-1177. Review.

PMID:
19661632
17.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
18.

Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.

Frankfort SV, Tulner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen JH.

Curr Clin Pharmacol. 2008 May;3(2):123-31. Review.

PMID:
18700307
19.

[The progress of Alzheimer's disease research biomarkers--sensitivity and specificity].

Shoji M.

Rinsho Shinkeigaku. 2000 Dec;40(12):1234-6. Review. Japanese.

PMID:
11464465
20.

Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness.

Shoji M.

Front Biosci. 2002 Apr 1;7:d997-1006. Review.

PMID:
11897565
Items per page

Supplemental Content

Write to the Help Desk